New brain link as cause of schizophrenia

In work published today in the Proceedings of the National Academy of Sciences, the team has found that NMDA receptors are essential in modifying brain oscillations – electrical wave patterns – which are altered in patients with schizophrenia.

They now want to investigate whether optimising the function of the receptors, which are already know to be involved in making memories, could lead to a new way of treating the mental illness.

Schizophrenia is one of the most common serious mental health conditions in the UK and can cause a range of different psychological symptoms, including hallucinations and delusions. One in 100 people will experience at least one episode of acute schizophrenia during their lifetime and it affects men and women equally. While its exact cause is unknown, most experts believe that the condition is caused by a combination of genetic and environmental factors.

Dr Mark Cunningham, who led the research at Newcastle University, UK, says: "We have shown that by selectively targeting receptors we can modify the dynamics of the brain. Our hope would be that in the long term this could lead to a method for actually improving brain function, not only for people with schizophrenia but potentially for many other brain conditions.

"We intend to continue looking in more detail at brain receptors so we can build on our understanding of how the brain works. This could open a new route for the design of drugs and a better understanding of how existing drugs work."

The brain is capable of producing different types of cortical oscillations. The Newcastle University team has identified a difference in one particular type - termed a gamma frequency oscillation - which has previously been shown to be altered in schizophrenia patients.

They examined the function of individual brain neurons in rats and applied ketamine, a drug which mimics many of the symptoms of schizophrenia in humans and animals and which is also a common recreational drug. They found that ketamine modified the frequency of cortical oscillations associated with normal brain function by blocking NMDA receptors.

NMDA receptors are already known to be involved in making memories. This new research demonstrates that the function of NMDA receptors on one particular type of brain cell, an inhibitory interneuron, is critically important for modifying the oscillation rate of the brain.

The Newcastle team believes that the disrupted patterns of oscillations seen in patients suffering from schizophrenia may be either due to this inhibitory brain neuron having a lack of NMDA receptors or that the NMDA receptors on this neuron are not functioning fully. As a result of this research, scientists have a whole new area to explore in the treatment of schizophrenia.

Source: Newcastle University

Brain compound 'throws gasoline onto the fire' of schizophrenia
New research has traced elevated levels of a specific compound in the brain to problem-solving deficits in patients with schizophrenia.
Researchers identify new target in brain for treating schizophrenia
Research from the University of Pittsburgh could expand the options for controlling schizophrenia by identifying a brain region that responds to more than one type of antipsychotic drug. The findings illustrate for the first time that the orbitofrontal cortex could be a promising target for developing future antipsychotic drugs—even those that have very different mechanisms of action. The study will be published during the week of Nov. 3 in the online edition of the journal Proceedings of National Academy of Sciences, with a print version to follow.
Membrane fusion at the synapse: Janus faced synaptotagmin-1 helps to keep the fast pace
Imagine a bathtub with two soap bubbles colliding but never fusing. Then you add detergent, and the surface of the water goes flat as the walls of the bubbles collapse and merge.
Scientists engineer supersensitive receptor, gain better understanding of dopamine system
Genetically modifying a receptor found on the neurons that produce the neurotransmitter dopamine has given California Institute of Technology (Caltech) researchers a unique glimpse into the workings of the brain's dopamine system--as well as a new target for treating diseases that result from either too much or too little of this critical neurotransmitter.
Biophysicists create new model for protein-cholesterol interactions in brain and muscle tissue
Biophysicists at the University of Pennsylvania have used 3,200 computer processors and long-established data on cholesterol's role in the function of proteins to clarify the mysterious interaction between cholesterol and neurotransmitter receptors. The results provide a new model of behavior for the nicotinic acetylcholine receptor, a well studied protein involved in inflammation, Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy, the effect of general anesthetics and addiction to alcohol, nicotine and cocaine.
Memory enhanced by sports-cheat drug
A drug used to increase blood production in both medical treatments and athletic doping scandals seems also to improve memory in those using it. New research published in the open access journal BMC Biology shows that the memory enhancing effects of erythropoietin (EPO) are not related to its effects on blood production but due to direct influences on neurons in the brain. The findings may prove useful in the treatment of diseases affecting brain function, such as schizophrenia, multiple sclerosis, and Alzheimer's.
Protein on 'speed' linked to ADHD
A genetic change in the dopamine transporter – one of the brain's dopamine-handling proteins – makes it behave as if amphetamine is present and "run backward," Vanderbilt University Medical Center investigators report this week in The Journal of Neuroscience.
Patterns of normal brain activity may predispose individuals to different symptoms of psychosis
A new study released today offers a potential predictive technique to anticipate how individuals might behave during a psychotic episode. The study, in the June 18 issue of The Journal of Neuroscience, related the brain activity of healthy participants to how they behaved after exposure to ketamine (a psychosis-inducing drug that mimics schizophrenia symptoms). The findings help explain why schizophrenia symptoms vary greatly from person to person and may ultimately help personalize diagnosis and intervention.

New brain link as cause of schizophrenia

Related stories:

News discussion: